Because MCF-7 cells overexpressing HRG are estradiol-independent and acquire an anti-estrogen therapy-resistant phenotype [12,13,14], we explored whether exacerbated FASN activity might serve as part of the HRG-driven endocrine resistance program in breast cancer cells. This evidence concerns the gene FASN and breast cancer.